ライフサイエンスコーパス: mofetil

1 urin inhibitors, steroids, and mycophenolate mofetil.

2 of rapamycin, tacrolimus, and mycophenolate mofetil.

3 , male sex, and treatment with mycophenolate mofetil.

4 g of tacrolimus, steroids, and mycophenolate mofetil.

5 munosuppression with FK506 and mycophenolate mofetil.

6 dogs received cyclosporine and mycophenolate mofetil.

7 ts given cyclophosphamide than mycophenolate mofetil.

8 duction and were maintained on mycophenolate mofetil.

9 ion regimens of tacrolimus and mycophenolate mofetil.

10 ts treated with tacrolimus and mycophenolate mofetil.

11 then stopped), tacrolimus and mycophenolate mofetil.

12 cyclosporine or tacrolimus and mycophenolate mofetil.

13 ansplantation cyclosporine and mycophenolate mofetil.

14 calcineurin antagonists and/or mycophenolate mofetil.

15 There is an increased use of mycophenolate mofetil.

16 be blocked by the presence of mycophenolate mofetil.

17 then steroids, tacrolimus, and mycophenolate mofetil.

18 ssion (IS) with tacrolimus and mycophenolate mofetil.

19 n, tacrolimus, prednisone, and mycophenolate mofetil.

20 ized to methotrexate and 39 to mycophenolate mofetil.

21 ents receiving methotrexate or mycophenolate mofetil.

22 and GVHD immunoprophylaxis of mycophenolate mofetil (1 g three times a day, days 0-28) and tacrolimu

23 trexate, 25 mg weekly, or oral mycophenolate mofetil, 1 g twice daily, and were followed up monthly f

24 Tacrolimus, 4 mg/d, and mycophenolate mofetil, 1.0 g/d, versus intravenous cyclophosphamide wi

25 /d, tapered over 6 months, and mycophenolate mofetil, 1000 mg twice daily, for a mean of 24.3 months.

26 rradiation, cyclosporine A and mycophenolate mofetil (12 doses), and antilymphocyte serum (one dose);

27 , sirolimus 8 to 12 ng/mL with mycophenolate mofetil 2 g two times per day.

28 , phase 3 study comparing oral mycophenolate mofetil (2 g per day) and oral azathioprine (2 mg per ki

29 immunosuppression consisted of mycophenolate mofetil (28 days) and cyclosporine (35 days).

30 nagement Study (ALMS) trial of mycophenolate mofetil, 3) the Lupus Nephritis Assessment with Rituxima

31 ized to methotrexate and 16 to mycophenolate mofetil; 30 had acute VKH.

32 er with azathioprine than with mycophenolate mofetil (39.6% vs. 25.2%, P = 0.02).

33 h planned low-dose maintenance mycophenolate mofetil (500 mg twice daily) and tacrolimus (targeted tr

34 and an antimetabolite, mostly mycophenolate mofetil (91.7%).

35 6, 9.8; P = .20) the odds with mycophenolate mofetil, a difference that was not statistically signifi

36 al [CI] 2.03-6.39), Neoral and mycophenolate mofetil (AHR 2.09, CI 1.31-3.31), and sirolimus and myco

37 1.31-3.31), and sirolimus and mycophenolate mofetil (AHR 2.77, CI 1.40-5.47), were associated with d

38 ed mycophenolate sodium versus mycophenolate mofetil along with reduced maintenance tacrolimus dosing

39 arget of rapamycin [mTOR]) and mycophenolate mofetil (an inosine monophosphate dehydrogenase inhibito

40 A) is the active metabolite of mycophenolate mofetil, an effective immunosuppressive drug.

41 lease tacrolimus, basiliximab, mycophenolate mofetil and 1 bolus of intraoperative corticosteroids (0

42 (11%) patients died (five [7%] mycophenolate mofetil and 11 [15%] cyclophosphamide), with most due to

43 maintenance treatment (116 to mycophenolate mofetil and 111 to azathioprine).

44 ing immunosuppression included mycophenolate mofetil and a calcineurin inhibitor.

45 steroid-sparing agents such as mycophenolate mofetil and a new class of immunomodulatory agents targe

46 , followed by maintenance with mycophenolate mofetil and an intensively dosed alphaCD40 (2C10R4) anti

47 Large controlled trials using mycophenolate mofetil and azathioprine for maintenance therapy have be

48 ional immunomodulators such as mycophenolate mofetil and biologics such as rituximab are effective in

49 er day (Arm 3; n=304) all with mycophenolate mofetil and corticosteroids (tapered) over 24 weeks, or

50 acebo, both on a background of mycophenolate mofetil and corticosteroids.

51 oved significantly in both the mycophenolate mofetil and cyclophosphamide groups.

52 GVHD prophylaxis was mycophenolate mofetil and cyclosporine.

53 or placebo, on a background of mycophenolate mofetil and glucocorticoids.

54 ents received cyclosporine and mycophenolate mofetil and gradually tapered prednisone.

55 urvivals after introduction of mycophenolate mofetil and induction with basiliximab.

56 difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide in ameliorating

57 osuppressive substance in both mycophenolate mofetil and mycophenolate sodium, and it is widely used

58 suggest that a combination of mycophenolate mofetil and prednisone may be an effective treatment for

59 ground of negative trials with mycophenolate mofetil and rituximab, there are recent data demonstrati

60 o oral steroids can be used in mycophenolate mofetil and rituximab-based regimes.

61 ALPS-specific toxicities, and mycophenolate mofetil and sirolimus have been demonstrated to have mar

62 ith tacrolimus with or without mycophenolate mofetil and steroids.

63 50% reduction in doses of both mycophenolate mofetil and Tac without antiviral therapy.

64 nosuppression with maintenance mycophenolate mofetil and tacrolimus between October 2008 and January

65 ll-depleting agent followed by mycophenolate mofetil and tacrolimus is presently the most frequently

66 Mean doses reduction of mycophenolate mofetil and tacrolimus were 44% and 41%, respectively, f

67 Mycophenolate mofetil and TNF-alpha antagonists can be used in case of

68 tients received tacrolimus and mycophenolate mofetil and underwent a 5-day glucocorticoid taper in a

69 rexate or 1 g twice daily oral mycophenolate mofetil and were monitored monthly for 6 months.

70 ) dose or conversion to either mycophenolate mofetil and/or rapamycin resulted in variable results an

71 rolimus/cyclosporine (FK/CSA), mycophenolate mofetil, and a rapid steroid taper.

72 s disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphas

73 nance therapy with tacrolimus, mycophenolate mofetil, and corticosteroids.

74 n combination with tacrolimus, mycophenolate mofetil, and corticosteroids.

75 eceived basiliximab induction, mycophenolate mofetil, and corticosteroids.

76 RDP using thymoglobulin, mycophenolate mofetil, and CsA in selected pediatric KTx recipients is

77 ff over 6 days, thymoglobulin, mycophenolate mofetil, and cyclosporine A (CsA).

78 ation consisted of tacrolimus, mycophenolate mofetil, and glucocorticoids.

79 yclophosphamide, azathioprine, mycophenolate mofetil, and methotrexate.

80 istributed among azathioprine, mycophenolate mofetil, and methotrexate.

81 received cyclophosphamide and mycophenolate mofetil, and more children with JIA received interleukin

82 me consisting of cyclosporine, mycophenolate mofetil, and prednisolone were well tolerated and equall

83 mus combined with basiliximab, mycophenolate mofetil, and prednisolone.

84 ethylprednisolone, tacrolimus, mycophenolate mofetil, and prednisone were commenced.

85 Patients taking cyclosporine, mycophenolate mofetil, and prednisone were randomly assigned to receiv

86 mmunotherapy using tacrolimus, mycophenolate mofetil, and prednisone.

87 ssive therapy with tacrolimus, mycophenolate mofetil, and prednisone.

88 hymocyte globulin, tacrolimus, mycophenolate mofetil, and prednisone.

89 ssion consisted of tacrolimus, mycophenolate mofetil, and rapidly tapered solumedrol with few excepti

90 lobulin induction, tacrolimus, mycophenolate mofetil, and steroid withdrawal by day 5 after transplan

91 were maintained on tacrolimus, mycophenolate mofetil, and steroid.

92 followed by de novo sirolimus, mycophenolate mofetil, and steroids were compared; group 1: 204 patien

93 ntibody followed by sirolimus, mycophenolate mofetil, and steroids.

94 n combination with tacrolimus, mycophenolate mofetil, and steroids.

95 nosuppression with tacrolimus, mycophenolate mofetil, and steroids.

96 obulin, calcineurin inhibitor, mycophenolate mofetil, and steroids.

97 regimens consisting of a CNI, mycophenolate mofetil, and steroids; therefore, CNI withdrawal not onl

98 on high-dose cyclophosphamide, mycophenolate mofetil, and tacrolimus or sirolimus.

99 ppression was with prednisone, mycophenolate mofetil, and tacrolimus.

100 oups consisting of prednisone, mycophenolate mofetil, and tacrolimus.

101 plete allografting, then PTCy, mycophenolate mofetil, and tacrolimus.

102 Both MPA and mycophenolate mofetil are highly specific inhibitors of guanine nucleo

103 Calcineurin inhibitors and mycophenolate mofetil are potential salvage therapies, and reagents su

104 Tacrolimus and mycophenolate mofetil are promising therapies for problematic patients

105 pression with cyclosporine and mycophenolate mofetil as a control group, we compared outcomes with ex

106 atient survival and the use of mycophenolate mofetil as part of maintenance immunosuppression was ass

107 Clinical trials evaluating mycophenolate mofetil as remission induction therapy, gusperimus, beli

108 Mycophenolate mofetil at intensified and individually adjusted dose in

109 ed mycophenolate sodium versus mycophenolate mofetil at month 6 among African Americans and at month

110 KTRs maintained on tacrolimus/mycophenolate mofetil-based regimen along with steroid.

111 imus QD 0.2 mg/kg per day with mycophenolate mofetil, basiliximab, and corticosteroids given only per

112 and the present preference for mycophenolate mofetil because of its better tolerability and toxicity

113 Mycophenolate mofetil, budesonide, rapamycin, and 6-thioguanine are pr

114 alcineurin inhibitor (CNI) and mycophenolate mofetil by 30% to 50% (n=23), or we switched from CNI to

115 with IFN-beta-1a (Avonex) and mycophenolate mofetil (Cellcept) modulated the hyperphosphorylation of

116 induction with tacrolimus and mycophenolate mofetil combination maintenance, both regimens using ste

117 patients (35 methotrexate, 32 mycophenolate mofetil) contributed to the primary outcome.

118 essive regimen, when used with mycophenolate mofetil, corticosteroids, and anti-interleukin-2 recepto

119 regimen, including sirolimus, mycophenolate mofetil, corticosteroids, and anti-interleukin-2 recepto

120 monly used in combination with mycophenolate mofetil, CsA, or TAC.

121 or antibody for induction, and mycophenolate mofetil, cyclosporin A, and prednisone for maintenance.

122 late mofetil versus tacrolimus+mycophenolate mofetil de novo, and (d) conversion from CNI to SRL vers

123 ia responses to cyclosporin or mycophenolate mofetil/dexamethasone.

124 Mycophenolate mofetil did not provide mycophenolic acid absorption as

125 Neither mycophenolate mofetil dose nor tacrolimus dose or trough levels were d

126 Mycophenolate mofetil dose reduction was independently associated with

127 o 275 ng/mL, respectively, and mycophenolate mofetil dose was adjusted according to 2 to 4 week surve

128 or more than 2000 mg per day (mycophenolate mofetil equivalents) was significantly higher with enter

129 Tacrolimus or sirolimus and mycophenolate mofetil exposure was identical between groups.

130 interstitial lung disease with mycophenolate mofetil for 2 years or cyclophosphamide for 1 year both

131 200 cGy) with cyclosporine and mycophenolate mofetil for posttransplantation immunoprophylaxis.

132 s of both cyclophosphamide and mycophenolate mofetil for progressive scleroderma-related interstitial

133 titis C virus reinfection, and mycophenolate mofetil-free regimens were significant risk factors for

134 lapses were more common in the mycophenolate mofetil group (42/76 patients) compared with the azathio

135 ne to 24 months by 2.19 in the mycophenolate mofetil group (95% CI 0.53-3.84) and 2.88 in the cycloph

136 ts in 8 patients (7.5%) in the mycophenolate mofetil group (HR, 0.53 [95% CI, 0.23-1.18]; P = .12).

137 p and in 23.5% of those in the mycophenolate mofetil group (P = 0.11), and the rate of withdrawal due

138 4% (19 of 116 patients) in the mycophenolate mofetil group and 32.4% (36 of 111) in the azathioprine

139 plant recipients receiving 2 g mycophenolate mofetil (group A, n=75) versus 1.440 g enteric-coated my

140 nd, in contrast to budesonide, mycophenolate mofetil has been effective in a small study of problemat

141 Mycophenolate mofetil has emerged as a viable alternative to cyclophos

142 Mycophenolate mofetil has not become the "wonder drug" that had been a

143 , P=0.003) and with the use of mycophenolate mofetil (HR=0.77, 95% CI 0.64-0.92, P=0.005).

144 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0.21-2.03) had

145 pheresis, rituximab, sirolimus, mycofenolate mofetil, imatinib, pentostatin and infusion of mesenchym

146 ing regimen with sirolimus and mycophenolate mofetil immune suppression.

147 ort course of cyclosporine and mycophenolate mofetil immunosuppression.

148 e tacrolimus, basiliximab, and mycophenolate mofetil immunosuppressive regimen is efficacious, with a

149 mprovers were downregulated in mycophenolate mofetil improvers, suggesting that immunomodulatory or c

150 We compared Everolimus versus mycophenolate mofetil in an investigator-initiated single-center trial

151 observed in patients receiving mycophenolate mofetil in any treatment combination (HR 0.80, P=0.438 f

152 a demonstrating superiority of mycophenolate mofetil in certain subgroups.

153 icosteroids, azathioprine, and mycophenolate mofetil in ocular myasthenia gravis.

154 ts of the use of rituximab and mycophenolate mofetil in resistant disease.

155 Mycophenolate mofetil is a potent immunosuppressant medication approve

156 est that the immunosuppressant mycophenolate mofetil is associated with anemia.

157 lin induction, tacrolimus, and mycophenolate mofetil is associated with excellent patient and kidney

158 al lung disease (ILD), whereas mycophenolate mofetil is effective in both polymyositis and refractory

159 ), to test the hypothesis that mycophenolate mofetil is more effective than azathioprine for preventi

160 Mycophenolate mofetil is, therefore, a suitable alternative to cycloph

161 py, often with azathioprine or mycophenolate mofetil, is required to consolidate remission and preven

162 tion along with tacrolimus and mycophenolate mofetil maintenance.

163 rine, thalidomide analogs, and Mycophenalate Mofetil may also be effective in refractory CLE.

164 Immunosuppression included mycophenolate mofetil (MMF) (2 g/day), tacrolimus (target trough 4-8 n

165 reduced-dose cyclosporine, or mycophenolate mofetil (MMF) 3 g/day with standard-dose cyclosporine (p

166 enolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) among renal transplant recipients receivin

167 Mycophenolate mofetil (MMF) and combination therapies including MMF, a

168 Prophylactic drugs, such as mycophenolate mofetil (MMF) and cyclosporine A (CsA), are often used t

169 s initially maintained on Tac, mycophenalate mofetil (MMF) and prednisone.

170 safety of in utero exposure to mycophenolate mofetil (MMF) and sirolimus (SRL) in transplant recipien

171 ) or cyclosporine A (CsA) with mycophenolate mofetil (MMF) and steroids after heart transplantation (

172 imus (Tac) in combination with mycophenolate mofetil (MMF) and those maintained on a regimen of Tac a

173 enolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) and to examine the impact of dose manipula

174 Nowadays, tacrolimus (Tac) and mycophenolate mofetil (MMF) are considered more efficient than cyclosp

175 sing T- and B-cell markers and mycophenolate mofetil (MMF) dosage.

176 oid withdrawal, tacrolimus and mycophenolate mofetil (MMF) for 1 month followed by randomization to s

177 nicians are increasingly using mycophenolate mofetil (MMF) for the treatment of systemic lupus erythe

178 mus (Tac) and dose-intensified mycophenolate mofetil (MMF) further adjusted individually.

179 nhibitor (CNI) withdrawal with mycophenolate mofetil (MMF) has not become routine practice, due to co

180 Rapamycin and mycophenolate mofetil (MMF) have been used for maintenance immunosuppr

181 ermine whether the addition of mycophenolate mofetil (MMF) improves the efficacy of initial systemic

182 favorable long-term effects of mycophenolate mofetil (MMF) in renal transplantation, its introduction

183 aracterize dose adjustments of mycophenolate mofetil (MMF) in this setting.

184 study of daclizumab (DZB) and mycophenolate mofetil (MMF) including DZB(+)MMF(+), DZB(-)MMF(+), DZB(

185 and adverse effects caused by mycophenolate mofetil (MMF) inhibition may be genetically determined,

186 Mycophenolate mofetil (MMF) is an alternative to cyclophosphamide for

187 The use of mycophenolate mofetil (MMF) is associated with less acute rejection th

188 The prodrug ester mycophenolate mofetil (MMF) is frequently used in solid-organ and stem

189 enolate sodium (EC-MPS) versus mycophenolate mofetil (MMF) maintenance immunosuppression at the time

190 nt studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cycl

191 day 28 posttransplantation to mycophenolate mofetil (MMF) or Everolimus combined with cyclosporine A

192 , was designed to test whether mycophenolate mofetil (MMF) plus corticosteroids was superior to corti

193 Mycophenolate mofetil (MMF) provides superior prophylaxis against acut

194 Mycophenolate mofetil (MMF) side effects often prompt dose reduction o

195 induction with tacrolimus and mycophenolate mofetil (MMF) therapy in renal transplantation, we analy

196 onstrated that conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC

197 The benefit of conversion from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC

198 core (MRSS) improvement during mycophenolate mofetil (MMF) treatment.

199 Mycophenolate mofetil (MMF) use in renal transplantation has steadily

200 Mycophenolate mofetil (MMF) use may be associated with progressive mul

201 ve protocols: tacrolimus (Tac)/mycophonelate mofetil (MMF) versus Tac/ sirolimus (SRL).

202 fter basiliximab induction and mycophenolate mofetil (MMF) with steroids.

203 ess the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on ambulatory blood pressure mo

204 ned the effects of late CNI or mycophenolate mofetil (MMF) withdrawal on echocardiographic parameters

205 1999-2001 and then tacrolimus+mycophenolate mofetil (MMF)+daclizumab (steroid-free) vs. tacrolimus+M

206 Mycophenolate mofetil (MMF), a prodrug of mycophenolic acid (MPA), is

207 Mycophenolate Mofetil (MMF), a prodrug of mycophenolic acid, has clini

208 dosing with tacrolimus (TAC), mycophenolate mofetil (MMF), and corticosteroids.

209 crolimus/sirolimus, tacrolimus/mycophenolate mofetil (MMF), and cyclosporine/sirolimus.

210 sociation of tacrolimus (TAC), mycophenolate mofetil (MMF), and prednisone with BKN in renal allograf

211 us (FK) or cyclosporine (CSA), mycophenolate mofetil (MMF), and steroids versus no calcineurin inhibi

212 the combination of tacrolimus, mycophenolate mofetil (MMF), and steroids.

213 ts were initially treated with mycophenolate mofetil (MMF), cyclosporine A (CsA), and prednisone (pre

214 omparing early CW (tacrolimus, mycophenolate mofetil (MMF), daclizumab, and corticosteroids until day

215 mg/kg per day plus etanercept, mycophenolate mofetil (MMF), denileukin diftitox (denileukin), or pent

216 a 3-drug regimen consisting of mycophenolate mofetil (MMF), sirolimus, and the anti-IL-2 receptor ant

217 combination of tacrolimus and mycophenolate mofetil (MMF).

218 or EC-MPS were comparable with mycophenolate mofetil (MMF).

219 aintenance with tacrolimus and mycophenolate mofetil (MMF).

220 h either methotrexate (MTX) or mycophenolate mofetil (MMF).

221 ted with the immunosuppressant mycophenolate mofetil (MMF).

222 with both corticosteroids and mycophenolate mofetil (MMF).

223 cineurin inhibitor as follows: mycophenolate mofetil (MMF)/mycophenolate sodium+tacrolimus (TAC), MMF

224 us (FK-506, 0.1 mg/kg per day)/mycophenolate mofetil (MMF, 60 mg/kg per day), and anti-CD3 (50 mug/da

225 Immunosuppression included mycophenolate mofetil (MMF, n=16) and sirolimus (n=16).

226 s (FK506; 0.1-0.5-1 mg/kg ip), mycophenolate mofetil (MMF; 60-120-300 mg/kg oral) or vehicle for 14 d

227 ety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough lev

228 Prednisolone, tacrolimus, and mycophenolate mofetil modified fecal microbiota at the family level in

229 ed to azathioprine (n = 80) or mycophenolate mofetil (n = 76) and were followed up for a median of 39

230 re randomly assigned to either mycophenolate mofetil (n=69) or cyclophosphamide (n=73).

231 126 patients (mycophenolate mofetil [n=63] and cyclophosphamide [n=63]) with accepta

232 adjusted hazard ratio (HR) for mycophenolate mofetil of 1.69 (95% confidence interval [CI], 1.06-2.70

233 The effect of sirolimus or mycophenolate mofetil on NK cells was minimal.

234 MPA), the active metabolite of mycophenolate mofetil, on erythropoiesis in vitro.

235 Maintenance therapy included mycophenolate mofetil or azathioprine plus glucocorticoids in combinat

236 ystemic immunosuppression with mycophenolate mofetil or cyclosporine A.

237 gastrointestinal symptoms with mycophenolate mofetil or EC-MPS in combination with Tac and cyclospori

238 ed after treatment with either mycophenolate mofetil or intravenous cyclophosphamide.

239 ance regimen of tacrolimus and mycophenolate mofetil or mycophenolate sodium was associated with 25%

240 he regimen of cyclosporine and mycophenolate mofetil or mycophenolate sodium.

241 Whether treatments such as mycophenolate mofetil or statins have a role in prevention of lupus CV

242 o were male, nonwhite, or used mycophenolate mofetil or tacrolimus were more likely to be nonadherent

243 with methotrexate and 47% with mycophenolate mofetil (P = 0.09).

244 mean tacrolimus (P=0.0009) and mycophenolate mofetil (P=0.01) blood levels.

245 globulin induction followed by mycophenolate mofetil plus calcineurin inhibitors (n=28, with 7 also r

246 ce therapy with belatacept and mycophenolate mofetil plus induction with basiliximab and LFA-1 blocka

247 e randomized to cyclosporin or mycophenolate mofetil plus pulse oral dexamethasone with a primary out

248 protocol included tacrolimus, mycophenolate mofetil, prednisone, and antithymocyte globulins.

249 ment that included tacrolimus, mycophenolate mofetil, prednisone, and, for induction, antithymocyte g

250 sitioning to azathioprine from mycophenolate mofetil prior to pregnancy in patients with quiet lupus

251 ontrolled trial, International Mycophenolate Mofetil Protocol to Reduce Outbreaks of Vasculitides (IM

252 The Tricontinental Mycophenolate Mofetil Renal Transplantation Study was a double-blind r

253 s treated with five therapies: mycophenolate mofetil, rituximab, abatacept, nilotinib, and fresolimum

254 Monitored drugs were mycophenolate mofetil, sirolimus, or azathioprine.

255 combinations of cyclosporine, mycophenolate mofetil, sirolimus, or methotrexate after 1 Gy TBI and d

256 FK), cyclosporine A (CSA), and mycophenolate mofetil/sodium (MMF).

257 ine (starting at 2 mg/kg/d) or mycophenolate mofetil (starting at 2000 mg/d) after induction of remis

258 ged on a calcineurin inhibitor/mycophenolate mofetil/steroid-free immunosuppression.

259 ained on calcineurin inhibitor/mycophenolate mofetil/steroid-free regimen.

260 vo immunosuppressive treatment (mycofenolate mofetil, steroids, basiliximab) with delayed introductio

261 imab [Tac/Bas], 139 tacrolimus/mycophenolate mofetil [Tac/MMF], and 139 tacrolimus/MMF/steroids [trip

262 for 14 days with prednisolone, mycophenolate mofetil, tacrolimus, a combination of these 3 drugs, eve

263 under anti-thymocyte globulin-mycophenolate mofetil-tacrolimus protocol.

264 rleukin 2 receptor blocker and mycophenolate mofetil/tacrolimus (Tac)/prednisone was employed.

265 udy (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intravenous cyclopho

266 ocked design to receive either mycophenolate mofetil (target dose 1500 mg twice daily) for 24 months

267 Fewer patients on mycophenolate mofetil than on cyclophosphamide prematurely withdrew fr

268 Combined prednisone and mycophenolate mofetil therapy is a potentially effective treatment for

269 Switching from mycophenolate mofetil to leflunomide successfully cleared verrucae vul

270 agiosum who were switched from mycophenolate mofetil to leflunomide.

271 It compared the addition of mycophenolate mofetil to steroids vs steroids/placebo to treat newly d

272 hate dehydrogenase inhibitors (mycophenolate mofetil) to the immunosuppressive armamentarium, replaci

273 fter each infusion); rapamycin+mycophenolate mofetil treatment as maintenance therapy.

274 Immunosuppressant mycophenolate mofetil treatment of enriched IL-17A(+) cells from MSC-p

275 ral methotrexate weekly or 1 g mycophenolate mofetil twice daily, with a corticosteroid taper.

276 lly, delaying cyclosporine and mycophenolate mofetil until after MTX administration did not seem to s

277 ted of ATG, anti-CD154mAb, and mycophenolate mofetil until age 8 to 12 months.

278 mia rates were associated with mycophenolate mofetil use (p < 0.0001) and EBV viral capsid antigen po

279 ination at 3 months versus SRL+mycophenolate mofetil versus tacrolimus+mycophenolate mofetil de novo,

280 Mycophenolate mofetil was associated with PCP risk only in the RTR pop

281 Although mycophenolate mofetil was better tolerated and associated with less to

282 Mycophenolate mofetil was initiated postoperatively with delayed initi

283 Use of mycophenolate mofetil was inversely associated with vaccine response i

284 Among patients with AAV, mycophenolate mofetil was less effective than azathioprine for maintai

285 of a calcineurin inhibitor or mycophenolate mofetil was predictive for maintaining a DSA remission (

286 Mycophenolate mofetil was superior to azathioprine in maintaining a re

287 Mycophenolate mofetil was superior to azathioprine with respect to the

288 Mycophenolate mofetil was the treatment in 10 patients, and in 5 of th

289 ombination with tacrolimus and mycophenolate mofetil, was first demonstrated after nonmyeloablative c

290 lin induction, tacrolimus, and mycophenolate mofetil were also associated.

291 is, CMV serostatus, and use of mycophenolate mofetil were each associated with risk of developing CMV

292 Tacrolimus and mycophenolate mofetil were required as well as either rabbit antithymo

293 ore transplant; tacrolimus and mycophenolate mofetil were started 1 week before surgery.

294 protocol with cyclosporine and mycophenolate mofetil were used for comparison.

295 A calcineurin inhibitor and mycophenolate mofetil were used for postgrafting immunosuppression.

296 al tacrolimus, prednisone, and mycophenolate mofetil, which has continued until the present day (22 m

297 such as biological agents and mycophenolate mofetil, will also be discussed.

298 uppression with tacrolimus and mycophenolate mofetil with/without steroids.

299 on consisted of tacrolimus and mycophenolate mofetil without induction or depletional therapies.

300 esised that a 2 year course of mycophenolate mofetil would be safer, better tolerated, and produce lo